title: Induction of natural killer (NK) activity in mice by injection of chromomycin A3.
abstract: Intravenously or intraperitoneally administered Chromomycin A3 (CHRM), an anticancer drug, augmented natural killer (NK) activity of both spleen cells and peritoneal exudate cells in BALB/c mice. When CHRM was administered intravenously, NK activity increased to about five fold that in nontreated mice on the 3rd to the 5th day, then rapidly decreased by the 7th day. On the other hand, when CHRM was administered by the intraperitoneal route, a peak of increased NK activity was observed on 5th to 7th day followed by a more gentle decrease. Augmentation of NK activity by CHRM was enhanced by additional administration of Interferon- gamma (IFN-gamma). Experimental evidence that NK activity could be augmented by CHRM in various strains of mice, independent of H-2 haplotype, suggested that involvement of genetic control within class I region of major histocompatibility complex could be excluded. When BALB/c mice inoculated subcutaneously with Meth A cells were treated with i.p. injection of CHRM, or CHRM in combination with IFN-gamma, the growth of the tumor cells was inhibited, indicating in vivo significance for the increased NK activity. Since this inhibitory effect was decreased by the injection of anti Asialo GM1 antibody (alpha-ASGM1), the effector cells presumably exerting killing activity against Meth A cells were concluded to be Asialo GM1 antigen positive.
authors.affiliation: Department of Clinical Cancer Chemotherapy, Tohoku University, Sendai.
authors.forename: M
authors.initials: M
authors.lastname: Kambe
authors.forename: R
authors.initials: R
authors.lastname: Kanamaru
authors.forename: Y
authors.initials: Y
authors.lastname: Mitachi
authors.forename: A
authors.initials: A
authors.lastname: Wakui
mesh_terms: D000818:Animals; D001202:Ascitic Fluid / Q000166:cytology; D001345:Autoradiography; D002478:Cells, Cultured; D014128:Chromomycin A3 / Q000008:administration & dosage / Q000494:pharmacology*; D005354:Fibrosarcoma / Q000276:immunology / Q000628:therapy; D005677:G(M1) Ganglioside; D005805:Genes, MHC Class I; D006028:Glycosphingolipids / Q000032:analysis / Q000276:immunology; D007371:Interferon-gamma / Q000008:administration & dosage / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D013154:Spleen / Q000166:cytology
chemical_list: D006028:Glycosphingolipids; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside; D007371:Interferon-gamma; D014128:Chromomycin A3